3D-Printed Films and Personalized Dosing: The Future of Supplement Strips

The supplement industry runs almost entirely on two formats: pills and powders. Both are decades-old technologies. Meanwhile, pharmaceutical researchers have been 3D-printing precise, dissolving oral films in laboratories around the world, tuning doses down to fractions of a milligram. That technology is now close enough to commercial reality that it deserves a serious look at what it means for the future of supplement delivery.

We are not a 3D-printing company. We make dissolvable strips using conventional manufacturing. But we pay close attention to the science of oral film delivery because that is the format we chose to build around, and the research happening in this space will shape what every strip on the market looks like in five to ten years.

What Are 3D-Printed Supplement Films?

3D-printed oral films are thin, dissolvable strips produced layer by layer using a digital design file instead of a traditional mold or casting tray. A printer deposits a formulation, typically a gel or paste containing active ingredients and a film-forming polymer, onto a surface in a precise pattern. The result is a strip that dissolves on the tongue, much like the ones already on the market, but with a level of dose customization that conventional manufacturing cannot easily match.

The concept is not theoretical. In 2015, the FDA approved Spritam (levetiracetam), manufactured by Aprecia Pharmaceuticals using a process called ZipDose technology. Spritam is a 3D-printed tablet for epilepsy that dissolves in the mouth with a sip of water. It remains the only FDA-approved 3D-printed drug on the market, and its approval established the regulatory precedent that additive manufacturing can meet pharmaceutical-grade quality standards.

For supplement films specifically, the research has accelerated since 2023. Semi-solid extrusion, or SSE, has emerged as the leading technique because it operates at room or mildly elevated temperatures, which matters when you are working with heat-sensitive ingredients like probiotics, certain B vitamins, or botanical extracts.

Semi-Solid Extrusion: The Printing Method Built for Films

Semi-solid extrusion is the 3D-printing method most relevant to dissolving films. It works by pushing a gel or paste through a fine nozzle, depositing it in programmed patterns onto a flat surface. Unlike fused deposition modeling, which melts thermoplastic filaments at 120 to 250 degrees Celsius, SSE can operate at ambient temperatures. That single difference opens the door to printing with ingredients that would degrade under heat.

A 2025 study published in Pharmaceutical Research by Poudel and colleagues compared two SSE approaches head to head: pneumatic extrusion (using air pressure) and syringe-based extrusion (using mechanical force). Both methods produced orodispersible films loaded with sumatriptan succinate. The pneumatic films disintegrated in roughly 55 seconds. The syringe films took about 65 seconds. Drug content in both cases fell within 95 to 105 percent of the target dose (Poudel et al., Pharmaceutical Research, 2025).

The practical difference came down to speed and consistency. Pneumatic printing produced a single film in three to four minutes. Syringe printing took about five minutes per film. Both methods delivered comparable drug release profiles, meaning the active ingredient dissolved out of the film at the same rate regardless of how it was deposited.

How Precise Can a Printed Dose Be?

Precision is where 3D printing genuinely outperforms conventional methods. In traditional supplement manufacturing, dose accuracy depends on blending powders uniformly before pressing them into tablets or filling them into capsules. That process works well at standard doses but struggles at very low amounts, where tiny variations in powder distribution can mean large percentage swings in what each individual unit contains.

3D printing sidesteps the blending problem entirely. The active ingredient is dissolved or suspended in the printing gel, so every drop that exits the nozzle carries a proportional amount of the dose. Researchers have demonstrated dosing accuracy within 93 to 105 percent of the target across multiple studies and printing methods. In one set of experiments using fused deposition modeling, carvedilol tablets were printed at 3.125, 6.25, and 12.5 milligrams with compliance to pharmacopeia standards for strength, dose accuracy, and dissolution (Bernatoniene et al., Pharmaceutics, 2025).

For oral films made by SSE, precision is even more striking at the low end of the scale. Researchers have printed films containing as little as 0.25 milligrams of active ingredient with measurable uniformity. That level of precision matters in contexts like pediatric dosing, where a child may need a fraction of an adult dose, or in personalized nutrition, where an individual's needs may call for a specific microgram quantity of a nutrient like vitamin D or melatonin.

The Polypill Problem and Why Personalization Matters

The case for personalized dosing is clearest in polypharmacy, the practice of taking multiple medications or supplements simultaneously. A 2025 review in the International Journal of Pharmaceutics: X found that polypharmacy affects more than half of older adults and is associated with approximately three times higher rates of adverse effects and nearly 50 percent medication non-adherence (Keerikkadu et al., Int J Pharm X, 2025).

The same review cited evidence that 3D-printed combination dosage forms, sometimes called polypills, could reduce pill burden by 60 to 70 percent and improve adherence by 30 to 40 percent. A polypill combines multiple active ingredients into a single unit, each with its own dose and potentially its own release profile. Instead of taking six separate capsules in the morning, a person could take one printed strip or tablet that delivers all six ingredients.

This is not just a convenience play. In the PolyIran cardiovascular trial, a four-in-one polypill reduced major cardiovascular events by 34 percent. Participants with high adherence to the polypill showed a hazard ratio of 0.43, meaning their risk was less than half that of the control group. The mechanism was not a better drug. It was a simpler routine.

The supplement world has the same adherence problem. The average person who buys a supplement takes it inconsistently, and the more products in the routine, the more likely something gets skipped. Personalized, combined-dose formats address the root cause: the friction of managing multiple bottles, each with its own dose schedule.

Where the Technology Stands Today

Several companies and research groups are actively working to bring 3D-printed supplements closer to market. Craft Health, a Singapore-based company, uses semi-solid extrusion to produce personalized nutraceutical and pharmaceutical dosage forms. Their system allows healthcare practitioners to specify the exact combination and dose of ingredients for an individual patient, which is then printed on demand. Weight variance in their printed products has been reported at 0.4 percent or less, a level of consistency that traditional compounding pharmacies rarely achieve.

In academic laboratories, the pace of publication has accelerated sharply. A 2025 review in Pharmaceutics documented active research programs using inkjet printing to deposit drug solutions onto edible substrates, creating oral films with precise, digitally controlled dosing. Researchers have successfully printed films containing salbutamol sulphate and warfarin, demonstrating that the technology works across different active ingredients and therapeutic categories (Bernatoniene et al., Pharmaceutics, 2025).

The regulatory picture is still developing. Beyond Spritam, no other 3D-printed oral product has received FDA approval. The 2025 polypills review noted that there is no clearly established global regulatory framework for approving and monitoring 3D-printed drugs or supplements. Batch-to-batch consistency, quality control under GMP conditions, and long-term stability data remain open questions that will need to be resolved before the technology scales.

What 3D Printing Cannot Do Yet

Honesty requires acknowledging the gaps. 3D-printed supplement films are not ready to replace conventional manufacturing at scale, and several serious limitations remain.

First, speed. The fastest SSE systems produce one film in three to four minutes. A conventional casting line can produce thousands of strips per hour. For a company shipping tens of thousands of units per month, 3D printing is orders of magnitude too slow unless it is reserved for small-batch, high-customization applications.

Second, regulatory clarity. The FDA's approval of Spritam established that 3D printing can meet pharmaceutical standards, but it did not create a streamlined pathway for every 3D-printed product that follows. Each new product would need to demonstrate its own process validation, bioequivalence, and quality controls. For supplements, which fall under different regulatory frameworks than drugs, the path is even less defined.

Third, material limitations. Not every active ingredient prints well. The formulation must be compatible with the printing gel, stable during deposition, and uniformly distributed in the final film. Some ingredients precipitate, degrade, or interact with the polymer matrix in ways that reduce potency or shelf life. The excipient library for 3D-printed oral films is still much smaller than what traditional manufacturing has available.

Fourth, cost. The equipment, formulation development, and per-unit production time make 3D-printed supplements significantly more expensive than their conventionally manufactured equivalents. That cost gap will narrow as the technology matures, but it is real today.

What This Means for the Supplement Strip Format

We make dissolving strips because we believe the format solves real problems: no pills to swallow, no water required, no sugar in the formula, and every dose printed on the label. The strips we ship today are made using conventional film casting, not 3D printing. But the research in 3D-printed oral films validates the format itself in ways that matter.

Every study cited in this article chose the dissolving film as its delivery platform. Researchers are not 3D-printing more pills. They are printing films, because films offer a thin, high-surface-area format that dissolves quickly, distributes ingredients uniformly, and lends itself to precise dosing. The academic investment in oral film technology is a signal that the format has a future beyond what the supplement industry has explored so far.

For our part, we are watching this research closely. Personalized dosing, combination formats, and on-demand manufacturing are all possibilities that 3D printing may eventually bring to the supplement category. We are not making promises about our own product roadmap based on laboratory research that has not yet been commercialized. What we can say is that the underlying science reinforces why we chose strips in the first place, and that the future of this format is being written in research labs right now.

The Regulatory Road Ahead

For 3D-printed supplements to reach consumers, several regulatory milestones will need to be met. Current Good Manufacturing Practice guidelines were written for traditional batch manufacturing. They assume large, uniform lots produced on validated equipment with established process parameters. 3D printing, by its nature, produces small, customized batches, sometimes as small as a single unit. That fundamental mismatch means regulators will need new frameworks for process validation, quality testing, and batch release.

The FDA has signaled interest. The agency's Emerging Technology Program has engaged with manufacturers exploring 3D printing for drug products. But guidance documents specific to 3D-printed supplements do not exist yet. In the European Union, the situation is similar: academic interest is high, commercial interest is growing, and regulatory frameworks are still catching up.

The most likely near-term path to market runs through compounding pharmacies and clinical nutrition settings, where personalized dosing already has a regulatory home and where the per-unit economics of 3D printing make more sense than mass manufacturing. A hospital printing a custom-dose dissolving film for a pediatric patient or an elderly patient on a complex regimen is a more realistic near-term application than a consumer brand shipping millions of personalized strips.

Frequently Asked Questions

Are 3D-printed supplements available to buy today?

Not widely. A small number of companies, such as Craft Health in Singapore, offer 3D-printed nutraceuticals through healthcare practitioners. No 3D-printed supplement has received FDA approval for direct-to-consumer sale in the United States. The technology is still primarily in research and limited clinical use.

How accurate is the dosing in a 3D-printed film?

Published studies report drug content within 93 to 105 percent of the target dose across multiple printing methods. Semi-solid extrusion, the method most used for films, has demonstrated weight variance as low as 0.4 percent. These figures meet or exceed the uniformity standards set by major pharmacopeias.

Is Spritam a supplement or a drug?

Spritam is a prescription drug (levetiracetam) for epilepsy, approved by the FDA in 2015. It is not a supplement. Its significance for the supplement industry is that it proved 3D printing can meet FDA manufacturing standards, establishing a regulatory precedent for the technology.

Could 3D printing make supplements cheaper?

Not in the near term. 3D printing is currently slower and more expensive per unit than conventional manufacturing. Its value lies in customization and precision, not cost reduction. Over time, as equipment costs decrease and throughput improves, the per-unit economics may improve, but traditional manufacturing will likely remain less expensive for standard products.

Do XYNE strips use 3D printing?

No. Our strips are manufactured using conventional film casting. We follow this research because it advances the science of oral film delivery, the format we already use. The studies in this article describe laboratory and early-commercial work that may shape the future of the supplement strip category.

Related Reading

• Oral Strips vs. Pills: The Format Guide
• Sublingual Films vs. Tablets vs. Lozenges
• The Dose Ceiling: How Much Can a Strip Hold?
• Nanoparticle Supplement Delivery: What the Research Actually Says
• Pill Fatigue: Why Adults Are Looking for Supplement Alternatives

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any supplement regimen.